Recombinant human growth hormone and brain neoplasm association: a pharmacovigilance and Mendelian randomization analysis based on US FAERS, Japanese JADER, and Canadian CVARD.

ABSTRACT:

Objective

This study aimed to analyze the statistical association between recombinant human growth hormone (rhGH) and brain neoplasm adverse events (AEs) by mining data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, the Japanese Adverse Drug Event Report (JADER) database, and the Canada Vigilance Adverse Reaction Online Database (CVARD). Furthermore, Mendelian randomization (MR) was utilized to evaluate the potential causal link between rhGH and brain neoplasm, thereby providing a reference for safe clinical medication use.

Methods

Reports of brain neoplasm associated with rhGH originated from the FAERS database (Q1 2004 - Q4 2024), the JADER database (April 2004 - December 2024), and the CVARD database (January 1991 - December 2024

SUBMITTER: Huang L 

PROVIDER: S-EPMC12339429 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature